Cargando…

The role of PARP inhibitors in BRCA mutated pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) accounts for about 3% of all cancers in the United States and about 7% of all cancer deaths. Despite the lower prevalence relative to other solid tumors, it is one of the leading causes of cancer-related death in the US. PDAC is highly resistant to chemotherap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chi, Jeffrey, Chung, Su Yun, Parakrama, Ruwan, Fayyaz, Fatima, Jose, Jyothi, Saif, Muhammad Wasif
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120537/ https://www.ncbi.nlm.nih.gov/pubmed/34025781 http://dx.doi.org/10.1177/17562848211014818

Ejemplares similares

Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer
por: Nicoletto, Maria Ornella, et al.
Publicado: (2023)

BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer
por: Pishvaian, Michael J, et al.
Publicado: (2017)

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
por: Annunziata, Christina M, et al.
Publicado: (2010)

Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors
por: Faraoni, Isabella, et al.
Publicado: (2018)

TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status
por: Ben Khaled, Najib, et al.
Publicado: (2022)

Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors
por: O’Sullivan, Ciara C., et al.
Publicado: (2014)

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting
por: Dziadkowiec, Karolina N., et al.
Publicado: (2017)

BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
por: Petrelli, Annalisa, et al.
Publicado: (2023)

PARP Inhibitors in Pancreatic Cancer: From Phase I to Plenary Session
por: Patel, Rajvi, et al.
Publicado: (2019)

PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival
por: Shao, Fengping, et al.
Publicado: (2021)

Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic Approaches
por: Dilmac, Sayra, et al.
Publicado: (2023)

Roles of the PARP Inhibitor in BRCA1 and BRCA2 Pathogenic Mutated Metastatic Prostate Cancer: Direct Functions and Modification of the Tumor Microenvironment
por: Inoue, Takahiro, et al.
Publicado: (2023)

Autoimmune response to PARP and BRCA1/BRCA2 in cancer
por: Zhu, Qing, et al.
Publicado: (2015)

PARP Inhibitor Insensitivity to BRCA1/2 Monoallelic Mutations in Microsatellite Instability-High Cancers
por: Sokol, Ethan S., et al.
Publicado: (2022)

Natural phytochemicals prevent side effects in BRCA-mutated ovarian cancer and PARP inhibitor treatment
por: Wang, Chuanlin, et al.
Publicado: (2022)

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance
por: Nesic, Ksenija, et al.
Publicado: (2023)

Attenuated regimen of biweekly gemcitabine/nab-paclitaxel in patients aged 65 years or older with advanced pancreatic cancer
por: Rehman, Hasan, et al.
Publicado: (2020)

Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
por: Stossel, Chani, et al.
Publicado: (2023)

PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
por: Konecny, G E, et al.
Publicado: (2016)

Clinical use of PARP inhibitor in recurrent uterine leiomyosarcoma with presence of a somatic BRCA2 mutation
por: Shammas, Natalie, et al.
Publicado: (2022)

Pancreatic Tuberculosis or Autoimmune Pancreatitis
por: Salahuddin, Ayesha, et al.
Publicado: (2014)

PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?
por: Frizzell, Kristine M, et al.
Publicado: (2009)

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
por: Colombo, Ilaria, et al.
Publicado: (2018)

Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status
por: Keung, Man Yee, et al.
Publicado: (2020)

PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond
por: Menezes, Maria Clara Saad, et al.
Publicado: (2022)

Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells
por: Moustafa, Dina, et al.
Publicado: (2021)

Differential responses to taxanes and PARP inhibitors in ATM‐ versus BRCA2‐mutated metastatic castrate‐resistant prostate cancer
por: Su, Christopher T., et al.
Publicado: (2022)

Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP Inhibition
por: Principe, Daniel R.
Publicado: (2022)

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
por: Castroviejo‐Bermejo, Marta, et al.
Publicado: (2018)

PARP-1 Expression and BRCA1 Mutations in Breast Cancer Patients’ CTCs
por: Sklias, Thodoris, et al.
Publicado: (2022)

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
por: Hodgson, Darren R., et al.
Publicado: (2018)

Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use
por: Abbotts, Rachel, et al.
Publicado: (2022)

A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers
por: Du, Tingting, et al.
Publicado: (2022)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
por: Yang, Shicheng, et al.
Publicado: (2023)

Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
por: Zatreanu, Diana, et al.
Publicado: (2021)

BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance
por: Nacson, Joseph, et al.
Publicado: (2018)

Efficacy and safety of PARP inhibitors in patients with BRCA-mutated advanced breast cancer: A meta-analysis and systematic review
por: Sun, Ximu, et al.
Publicado: (2021)

Metastatic Castration-Resistant Prostate Cancer with BRCA2 Mutation: The Challenge Incorporating PARP Inhibitors and Platinum in Treatment Sequencing
por: Nogueira Costa, Inês, et al.
Publicado: (2022)

BRCA1/2 Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents
por: Darabi, Sourat, et al.
Publicado: (2022)

Haploinsufficiency of ZNF251 causes DNA-PKcs-dependent resistance to PARP inhibitors in BRCA1-mutated cancer cells
por: Li, Huan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g56n4vo2jd4ggsf7ccl4ssva96